Drugs / Palomid 529
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01271270 | Dec 2010 → Sep 2012 | age-related macular degeneration | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 1 | NCT01033721 | Jun 2010 → Dec 2011 | age-related macular degeneration | Paloma Pharmaceuticals, Inc. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Palomid 529 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01271270 ↗ |
| Known as | P-529 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2141712 ↗ |
| Known as | SG 00529 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2141712 ↗ |
| Action | Inhibit | “dual TORC1/2 inhibitor” NCT01033721 ↗ |
| Modality | Small molecule | “Paloma Pharmaceuticals, Inc. has developed a non-steroidal, wholly synthetic, small molecule drug for application to diseases of aberrant neovasculature, known as Palomid 529.” NCT01271270 ↗ |
| Route | Intravitreal | “Single Intravitreal and Subconjunctival Doses of Palomid 529” NCT01033721 ↗ |
| Target | MTOR | “The experimental chemical Palomid 529 inhibits the production of mTOR.” NCT01271270 ↗ |